Product Theaters
Product Theaters feature exhibitor presentations on the clinical benefit or scientific research relating to the development of an approved pharmaceutical product and may include information on new uses, combinations, or therapies for the approved product. Sessions are non-CME and solely promotional in nature.
Unlocking the Benefits of Time-Off Treatment with a BCL-2 Inhibitor as the Proven Backbone of Targeted, Fixed-Duration Therapy in CLL
Sponsored by AbbVie
This presentation is intended for U.S. based registered meeting attendees
Saturday, December 6, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W208AB
For in-person participants only
Speaker:
Wendy Sinai, PharmD
Abbvie
Unlocking the Potential of CAR T: When and Why it Matters
Sponsored by Bristol Myers Squibb
This presentation is intended for U.S. based registered meeting attendees
Saturday, December 6, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W207BC
For in-person participants only
Speaker:
Amy Marsala, MPH, MS, ANP-BC
Bristol Myers Squibb
Frontline Therapy in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Sponsored by Johnson & Johnson
This presentation is intended for U.S. based registered meeting attendees
Saturday, December 6, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W203AB
For in-person participants only
Speaker:
Vipin Khare, MD
Johnson & Johnson
Hear Jen's Journey, Then Explore the Data
Sponsored by Novartis Pharmaceuticals Corporation
This presentation is intended for U.S. based registered meeting attendees
Saturday, December 6, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W204BC
For in-person participants only
This session will include a patient perspective
Speakers:
Vanita Patel, BS, MBA
Novartis Pharmaceuticals Corporation
Sheeba Paul, PharmD, MBA
Novartis Pharmaceuticals Corporation
A Treatment Option for Adults with Certain R/R DLBCL After ≥ 2 Prior Lines of Systemic Therapy
Sponsored by Pfizer Oncology
Saturday, December 6, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W209AB
For in-person participants only
Speaker:
Michelle Fanale, MD
Pfizer Oncology
Shifting Currents in Hemophilia Care: Exploring the Impact of Antithrombin Lowering
Sponsored by Sanofi
This presentation is intended for U.S. based registered meeting attendees
Saturday, December 6, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W206A
For in-person participants only
Speaker:
Amy Chen, PhD
Sanofi
Rapid NGS: Transforming Molecular Profiling of Myeloid and Lymphoid Malignancies
Sponsored by Thermo Fisher Scientific
Saturday, December 6, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W209C
For in-person participants only
Speakers:
Chris Allen, BSc
Thermo Fisher Scientific
Sophie Rozenzhak, PhD
Thermo Fisher Scientific
Transforming Thalassemia Care: Introducing a New Treatment Option from Agios Pharmaceuticals
Sponsored by Agios Pharmaceuticals
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
OCCC - W206A
For in-person participants only
Speaker:
Jeremie H. Estepp, MD
Agios Pharmaceuticals
A Consideration for Patients with Relapsed or Refractory Multiple Myeloma
Sponsored by Johnson & Johnson
This presentation is intended for U.S. based registered meeting attendees
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
OCCC - W208AB
For in-person participants only
Speaker:
Tonya Le Blanc, PhD
Johnson & Johnson
Advancing Care in RRMM: Clinical Evidence for a BCMA-Directed Bispecific Antibody Treatment Option (Program will begin with a patient’s own story)
Sponsored by Pfizer
This presentation is intended for U.S. based registered meeting attendees
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
OCCC - W209AB
For in-person participants only
This session will include a patient perspective
Speaker:
David Hughes, PharmD, BCOP, MPH
Pfizer
A New BsAb Treatment for R/R Multiple Myeloma After 4 Prior Lines
Sponsored by Regeneron
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
OCCC - W204BC
For in-person participants only
Speaker:
Tito Roccia, MD
Regeneron
Cablivi (caplacizumab-yhdp) Real-World Evidence in 1,000+ Patients: Early Initiation Matters
Sponsored by Sanofi
This presentation is intended for U.S. based registered meeting attendees
Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.
OCCC - W207BC
For in-person participants only
This session will include a patient perspective
Speakers:
Alessandro Ciarcia
Sanofi
Dina Issa, PharmD
Sanofi
Reignite the Spark: Clinical Conversations about Jaypirca (pirtobrutinib)
Sponsored by Eli Lilly and Company
This presentation is intended for U.S. based registered meeting attendees
Sunday, December 7, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W204BC
For in-person participants only
Speakers:
Sarang Abhyankar, MD
Eli Lilly and Company
John Pagel, MD, PhD
Eli Lilly and Company
Latest POLARIX Primary and 5-Year Outcomes Data
Sponsored by Genentech
Sunday, December 7, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W209AB
For in-person participants only
Speaker:
Connie Lee Batlevi, MD, PhD
Genentech
A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS
Sponsored by Geron Corporation
This presentation is intended for U.S. based registered meeting attendees
Sunday, December 7, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W207BC
For in-person participants only
Speaker:
Shyamala Navada, MD and MSCR
Geron Corporation
A New Treatment Option in Multiple Myeloma
Sponsored by GSK
This presentation is intended for U.S. based registered meeting attendees
Sunday, December 7, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W208AB
For in-person participants only
Speaker:
Elisabet Manasanch, MHSc
GSK
First-in-Class Treatment for Patients with Relapsed or Refractory Multiple Myeloma
Sponsored by Johnson & Johnson
This presentation is intended for U.S. based registered meeting attendees
Sunday, December 7, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W203AB
For in-person participants only
Speaker:
Ibrahim Saber, MD
Johnson & Johnson
Exploring a Subcutaneous Treatment Option in Hemophilia Care with HYMPAVZI (marstacimab-hncq)
Sponsored by Pfizer
This presentation is intended for U.S. based registered meeting attendees
Sunday, December 7, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W206A
For in-person participants only
Speakers:
Anu Gupta, PharmD
Pfizer
Sangeeta Raje, PhD
Pfizer
Jennifer Schumacher, PhD
Pfizer
Discover a New Way Forward with WAYRILZ
Sponsored by Sanofi
This presentation is intended for U.S. based registered meeting attendees
Sunday, December 7, 2025, 11:30 a.m. - 12:30 p.m.
OCCC - W209C
For in-person participants only
This session includes a patient perspective
Speakers:
Lika Dvali, MBA
Sanofi
Brad Ward, PharmD
Sanofi
Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+ FL
Sponsored by Genmab and AbbVie
This presentation is intended for U.S. based registered meeting attendees
Monday, December 8, 2025, 8:00 a.m. - 9:00 a.m.
OCCC - W209C
For in-person participants only
Speaker:
Felipe Marques Gonçalves, MD, MBA
Genmab
Introducing a Therapeutic Option in Relapsed/Refractory Acute Leukemia
Sponsored by Syndax Pharmaceuticals
This presentation is intended for U.S. based registered meeting attendees
Monday, December 8, 2025, 8:00 a.m. - 9:00 a.m.
OCCC - W208AB
For in-person participants only
Speakers:
Craig Freyer, PharmD, BCOP
Syndax Pharmaceuticals
Kim Tran, PharmD
Syndax Pharmaceuticals
First-Line Treatment Option for Anemia in Lower-Risk MDS COMMANDS Trial Overview
Sponsored by Bristol Myers Squibb
This presentation is intended for U.S. based registered meeting attendees
Monday, December 8, 2025, 12:15 p.m. - 1:15 p.m.
OCCC - W209C
For in-person participants only
Speaker:
Tracy Krimmel, DNP
Bristol Myers Squibb
MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients
Sponsored by Incyte Corporation
This presentation is intended for U.S. based registered meeting attendees
Monday, December 8, 2025, 12:15 p.m. - 1:15 p.m.
OCCC - W208AB
For in-person participants only
Speaker:
John Galvin, MD, MS, MPH
Incyte Corporation
Making the Case for Early Use of CAR-T Therapy in Multiple Myeloma
Sponsored by Johnson & Johnson
Monday, December 8, 2025, 12:15 p.m. - 1:15 p.m.
OCCC - W209AB
For in-person participants only
Speaker:
Deepu Madduri, MD
Johnson & Johnson
From Innovation to Impact: Real Stories of Transformation in PNH Management
Sponsored by Novartis Pharmaceuticals Corporation
Monday, December 8, 2025, 12:15 p.m. - 1:15 p.m.
OCCC - W207BC
This session will include a patient perspective
Speaker:
Jincy Paulose, MD
Novartis Pharmaceuticals Corporation
67th ASH Annual Meeting and exposition
Registration for ASH members, non-members, groups, exhibitors, and media is now open!